Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00295503
Status:
COMPLETED
Last Update Posted:
2020-10-20
First Post:
2006-02-22
Brief Title:
Cisplatin Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
A Phase II Trial of Cisplatin Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin pemetrexed and bevacizumab
Detailed Description:
Secondary endpoints will include
objective response rate
overall survival
In addition the objective of the analysis of the correlative science data is to determine any association between tumor expression of VEGFKDR complex andor the presence of sv40 as detected by PCR amplification and objective response
objective response rate
overall survival
In addition the objective of the analysis of the correlative science data is to determine any association between tumor expression of VEGFKDR complex andor the presence of sv40 as detected by PCR amplification and objective response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None